The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 11, 2023

Filed:

Nov. 01, 2018
Applicant:

Juno Therapeutics, Inc., Seattle, WA (US);

Inventors:

Blythe D. Sather, Seattle, WA (US);

Steven M. Shamah, Seattle, WA (US);

Yan Chen, Seattle, WA (US);

Rebecca Wu, Seattle, WA (US);

Collin Hauskins, Seattle, WA (US);

Csaba Pazmany, Seattle, WA (US);

Jui Dutta-Simmons, Seattle, WA (US);

Kimberly Harrington, Seattle, WA (US);

Assignee:

Juno Therapeutics, Inc., Seattle, WA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61P 35/00 (2006.01); C12N 15/867 (2006.01); C07K 14/535 (2006.01); C07K 14/705 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2875 (2013.01); A61P 35/00 (2018.01); C07K 14/535 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C12N 15/867 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01);
Abstract

Provided herein are BCMA-binding molecules, including anti-BCMA antibodies and antigen-binding fragments thereof such as heavy chain variable (VH) regions and single-chain antibody fragments, and chimeric receptors comprising the anti-BCMA binding molecules such as chimeric antigen receptors (CARs). In some embodiments, the anti-BCMA antibodies or antigen-binding fragments thereof specifically bind to BCMA-1. Among the anti-BCMA antibodies are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs or BCMA-binding molecules and uses thereof such as in adoptive cell therapy.


Find Patent Forward Citations

Loading…